{"organizations": [], "uuid": "7645a6fa6496e970489a3acbbe3f5139c04310c1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180501.html", "section_title": "Archive News &amp; Video for Tuesday, 01 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-releases-theratechnologies-fro/brief-fda-releases-theratechnologies-from-post-approval-commitments-related-to-egrifta-idUSASC09YK0", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Releases Theratechnologies From Post-Approval Commitments Related To EGRIFTA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.977, "site_type": "news", "published": "2018-05-01T19:46:00.000+03:00", "replies_count": 0, "uuid": "7645a6fa6496e970489a3acbbe3f5139c04310c1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-releases-theratechnologies-fro/brief-fda-releases-theratechnologies-from-post-approval-commitments-related-to-egrifta-idUSASC09YK0", "ord_in_thread": 0, "title": "BRIEF-FDA Releases Theratechnologies From Post-Approval Commitments Related To EGRIFTA", "locations": [], "entities": {"persons": [], "locations": [{"name": "co", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "theratechnologies inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1 (Reuters) - Theratechnologies Inc:\n* FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTAÂ® (TESAMORELIN FOR INJECTION)\n* THERATECHNOLOGIES - FDA DETERMINED LARGE-SCALE POST-APPROVAL TRIALS NO LONGER REQUIRED AS CURRENT LABELING ADEQUATELY REFLECTS SAFETY PROFILE OF EGRIFTA\n* THERATECHNOLOGIES - FOR YEAR ENDED NOV 30, 2017, CO ESTIMATED POST-APPROVAL COMMITMENTS WILL REQUIRE $13 MILLION INVESTMENT, WHICH WILL NO LONGER BE NEEDED Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-01T19:46:00.000+03:00", "crawled": "2018-05-02T16:05:41.000+03:00", "highlightTitle": ""}